Monashee Investment Management LLC Reduces Stock Position in Kymera Therapeutics, Inc. $KYMR

Monashee Investment Management LLC lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 64.9% during the 1st quarter, HoldingsChannel.com reports. The fund owned 35,100 shares of the company’s stock after selling 64,900 shares during the period. Kymera Therapeutics makes up approximately 1.6% of Monashee Investment Management LLC’s holdings, making the stock its 20th biggest holding. Monashee Investment Management LLC’s holdings in Kymera Therapeutics were worth $2,923,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. SG Americas Securities LLC boosted its position in Kymera Therapeutics by 169.1% in the 4th quarter. SG Americas Securities LLC now owns 22,693 shares of the company’s stock valued at $1,766,000 after buying an additional 14,261 shares during the period. State of New Jersey Common Pension Fund D bought a new position in Kymera Therapeutics in the 4th quarter worth about $2,610,000. Vanguard Group Inc. increased its position in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares during the period. Eagle Health Investments LP bought a new stake in shares of Kymera Therapeutics during the fourth quarter valued at approximately $10,606,000. Finally, Maven Securities LTD purchased a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $1,167,000.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. B. Riley Financial increased their price objective on Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Canaccord Genuity Group lifted their target price on Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a research report on Friday, June 26th. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Mizuho increased their price target on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Friday, July 17th. Twenty analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.64.

Insider Activity

In other Kymera Therapeutics news, Director Bruce Booth sold 467,878 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $110.29, for a total value of $51,602,264.62. Following the completion of the transaction, the director directly owned 472,267 shares in the company, valued at approximately $52,086,327.43. The trade was a 49.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Bruce N. Jacobs sold 77,109 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the sale, the chief financial officer directly owned 244,883 shares of the company’s stock, valued at approximately $28,151,749.68. The trade was a 23.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,637,813 shares of company stock valued at $390,253,404. Company insiders own 15.98% of the company’s stock.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $110.34 on Thursday. The company has a market cap of $9.08 billion, a PE ratio of -30.91 and a beta of 1.95. The firm’s 50 day moving average price is $95.15 and its 200-day moving average price is $86.12. Kymera Therapeutics, Inc. has a 52-week low of $36.65 and a 52-week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. During the same period in the prior year, the business posted ($0.82) EPS. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. On average, analysts forecast that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.